comparemela.com

Latest Breaking News On - நுழைவு இணைப்பு - Page 9 : comparemela.com

Breaking News: Uscreen Hits $100 Million Milestone

Breaking News: Uscreen Hits $100 Million Milestone
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Napo EU S p A , Jaguar Health s Italian Subsidiary, Provides Updates on Plans to Pursue Conditional Marketing Authorization in the EU

Napo EU S p A , Jaguar Health s Italian Subsidiary, Provides Updates on Plans to Pursue Conditional Marketing Authorization in the EU
theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.

Jaguar Health, Inc Reports 2021 First Quarter Financial Results

Jaguar Health, Inc. Reports 2021 First Quarter Financial Results ACCESSWIRE 17 May 2021, 22:05 GMT+10 First quarter 2021 Mytesi gross sales and net sales were approximately $4.6 million and approximately $1.2 million, increases of 250% and 43%, respectively Company to host investor webcast Monday, May 17th at 8:30 a.m. Eastern regarding first quarter 2021 financials & business updates SAN FRANCISCO, CA / ACCESSWIRE / May 17, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ( Jaguar or the Company ) today reported consolidated first quarter 2021 financial results. 2021 First Quarter Company Financial Results: Mytesi ® Net Product Revenue: Mytesi net sales during the first quarter of 2021 were approximately $1.2 million and $0.9 million in the first quarter of 2020. This first quarter 2021 result represents an increase of approximately 43% of the same period in 2020, or $0.3 million quarter over quarter. The increase in sales of Mytesi is due to the combined effect of the price adj

Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, June 11, 2021 and Encourages All Shareholders to Vote

Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, June 11, 2021 and Encourages All Shareholders to Vote ACCESSWIRE 14 May 2021, 22:43 GMT+10 Based on a preliminary review of votes cast, over 80% have voted in favor of Proposals 2, 3, 4 & 6 Meeting scheduled to reconvene June 11, 2021 at 8:30 AM Pacific Standard Time to provide time to reach quorum Reminder: Jaguar to host investor webcast Monday, May 17th at 8:30 AM Eastern Time regarding Q1 2021 financials & business updates SAN FRANCISCO, CA / ACCESSWIRE / May 14, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ( Jaguar or the Company ) today announced that its Annual Meeting of Stockholders held on May 13, 2021 (the Annual Meeting ) was adjourned due to a lack of quorum. The adjourned meeting will be held at 8:30 a.m. Pacific Standard Time/11:30 a.m. Eastern Standard Time on Friday, June 11, 2021, at the offices of the Company at 200 Pine Street, Suite 400, San Francisco, CA 94104. The record

Jaguar Health to Host Investor Webcast Monday, May 17th at 8:30 AM Eastern Time Regarding Q1 2021 Financials & Business Updates

Jaguar Health to Host Investor Webcast Monday, May 17th at 8:30 AM Eastern Time Regarding Q1 2021 Financials & Business Updates ACCESSWIRE Webcast registration link appears below Company plans to file Q1 2021 10-Q on May 17, 2021 SAN FRANCISCO, CA / ACCESSWIRE / May 11, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ( Jaguar or the Company ) today announced that Company management will host a webcast on Monday, May 17, 2021 at 8:30 a.m. Eastern Time to review first-quarter 2021 financials and provide business updates. Participation Instructions for Webcast Participant Registration & Access Link: About Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.